Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies (Q45746020)

15 December 2017

title

Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies (English)

1 reference

15 December 2017

0 references

4

Belshe RB

1 reference

15 December 2017

Geoffrey J Gorse

series ordinal

1

object named as

Gorse GJ

1 reference

15 December 2017

Gira B. Patel

series ordinal

2

object named as

Patel GB

1 reference

15 December 2017

author name string

Mandava MD

series ordinal

3

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

15 December 2017

number of pages

15

1 reference

inferred from page(s)

published in

Vaccine

1 reference

15 December 2017

volume

18

1 reference

15 December 2017

issue

9-10

1 reference

15 December 2017

page(s)

835-849

1 reference

15 December 2017

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

HIV versus cytotoxic T lymphocytes--the war being lost

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Cytotoxic T-cell immunity to influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900323-0

7 January 2021

10.1016/S0264-410X(99)00323-0

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

10580197

1 reference

15 December 2017